Norfloxacin Glutamate Injection

The main ingredient of this product is norfloxacin glutamate. Chemical name: 1-ethyl-6-fluoro-4-oxo-1,4-dihydro-7-(1-piperazinyl)-3-carboxylic acid quinoline glutamate Molecular formula: C16H18FN3O3·C5H9NO4 Molecular weight: 466.47

Suitable for respiratory tract and urinary tract infections, gonorrhea, prostatitis, intestinal infections, typhoid fever and other salmonella infections caused by sensitive bacteria

Adults: 0.2-0.4 g (1-2 vials) twice a day, intravenous drip at a rate of 30-40 drops/min, 7-14 days as a course of treatment

1. Gastrointestinal reactions are relatively common and may manifest as abdominal discomfort or pain, diarrhea, nausea or vomiting. 2. Central nervous system reactions may include dizziness, headache, drowsiness or insomnia. 3. Allergic reactions include rash, skin itching, facial flushing, chest tightness, etc. Exudative erythema multiforme and angioneurotic edema may occasionally occur. A small number of patients have photosensitivity reactions. 4. Occasionally, the following may occur: (1) Epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, and tremors. (2) Interstitial nephritis manifestations such as hematuria, fever, and rash. (3) Phlebitis. (4) Crystalluria, which is more common when used in high doses. (5) Joint pain. 5. A small number of patients may experience elevated serum aminotransferase, elevated blood urea nitrogen, and decreased peripheral white blood cells, which are mostly mild and transient.

1. Patients who are allergic to this product and quinolones are prohibited from using this product. 2. Pregnant women, lactating women and patients under 18 years old are prohibited from using this product.

1. Urine alkalinizers can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2. When this product is used in combination with theophylline, competitive inhibition of the binding site of cytochrome P450 may lead to a significant reduction in the liver clearance of theophylline, a prolonged blood elimination half-life, an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc. Therefore, the blood drug concentration of theophylline should be measured and the dose adjusted when used in combination. 3. Cyclosporine and this product can increase the blood drug concentration of the former. The blood concentration of cyclosporine must be monitored and the dose adjusted. 4. This product can enhance the anticoagulant effect of the latter when used with the anticoagulant warfarin. The patient's prothrombin time should be closely monitored when used in combination. 5. Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used in combination, it may cause toxicity due to the increased blood concentration of this product. 6. This product has an antagonistic effect with nitrofurantoin and is not recommended for combined use. 7. This product interferes with the metabolism of caffeine, resulting in reduced caffeine clearance, prolonged blood elimination half-life (t1/2β), and possible central nervous system toxicity.

2ml:0.2g (based on C16H18FN3O3)